Artiva Biotherapeutics (NASDAQ:ARTV) Director Buys $596,404.80 in Stock

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Director Ra Capital Management, L.P. acquired 59,880 shares of the firm’s stock in a transaction that occurred on Thursday, July 23rd. The stock was bought at an average price of $9.96 per share, with a total value of $596,404.80. Following the completion of the acquisition, the director directly owned 17,242,483 shares of the company’s stock, valued at $171,735,130.68. This trade represents a 0.35% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Ra Capital Management, L.P. also recently made the following trade(s):

• On Wednesday, July 22nd, Ra Capital Management, L.P. bought 84,124 shares of Artiva Biotherapeutics stock. The shares were bought at an average cost of $9.93 per share, for a total transaction of $835,351.32.
• On Tuesday, July 21st, Ra Capital Management, L.P. bought 120,582 shares of Artiva Biotherapeutics stock. The shares were bought at an average cost of $9.55 per share, for a total transaction of $1,151,558.10.
• On Friday, July 10th, Ra Capital Management, L.P. purchased 15,102 shares of Artiva Biotherapeutics stock. The stock was bought at an average price of $8.97 per share, for a total transaction of $135,464.94.
• On Monday, July 13th, Ra Capital Management, L.P. purchased 6,552 shares of Artiva Biotherapeutics stock. The stock was bought at an average cost of $8.94 per share, with a total value of $58,574.88.
• On Friday, June 26th, Ra Capital Management, L.P. acquired 1,876 shares of Artiva Biotherapeutics stock. The shares were bought at an average price of $8.98 per share, with a total value of $16,846.48.
• On Thursday, June 25th, Ra Capital Management, L.P. acquired 31,000 shares of Artiva Biotherapeutics stock. The shares were bought at an average price of $8.88 per share, with a total value of $275,280.00.
• On Tuesday, June 16th, Ra Capital Management, L.P. acquired 124,893 shares of Artiva Biotherapeutics stock. The stock was bought at an average cost of $8.89 per share, for a total transaction of $1,110,298.77.
• On Monday, June 15th, Ra Capital Management, L.P. bought 15,414 shares of Artiva Biotherapeutics stock. The stock was bought at an average price of $8.99 per share, for a total transaction of $138,571.86.
• On Friday, June 12th, Ra Capital Management, L.P. bought 391,019 shares of Artiva Biotherapeutics stock. The shares were purchased at an average cost of $8.57 per share, with a total value of $3,351,032.83.
• On Thursday, June 11th, Ra Capital Management, L.P. bought 548,580 shares of Artiva Biotherapeutics stock. The shares were purchased at an average cost of $7.91 per share, with a total value of $4,339,267.80.

Artiva Biotherapeutics Stock Up 0.6%

Artiva Biotherapeutics stock traded up $0.06 during mid-day trading on Tuesday, hitting $10.38. 193,057 shares of the stock were exchanged, compared to its average volume of 388,732. The stock has a market capitalization of $256.59 million, a price-to-earnings ratio of -2.95 and a beta of 2.18. Artiva Biotherapeutics, Inc. has a 12 month low of $2.22 and a 12 month high of $14.53. The firm’s fifty day simple moving average is $8.83 and its two-hundred day simple moving average is $7.37.

Artiva Biotherapeutics (NASDAQ:ARTV) last posted its quarterly earnings data on Friday, May 8th. The company reported ($0.95) earnings per share for the quarter, missing the consensus estimate of ($0.88) by ($0.07). As a group, analysts forecast that Artiva Biotherapeutics, Inc. will post -2.45 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on ARTV. Weiss Ratings reissued a “sell (d-)” rating on shares of Artiva Biotherapeutics in a research note on Tuesday, July 21st. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Artiva Biotherapeutics in a research note on Tuesday, May 26th. Wall Street Zen downgraded Artiva Biotherapeutics from a “hold” rating to a “sell” rating in a report on Sunday, May 17th. Needham & Company LLC reissued a “buy” rating and issued a $41.00 price target on shares of Artiva Biotherapeutics in a research note on Monday, June 8th. Finally, Wedbush increased their price target on Artiva Biotherapeutics from $23.00 to $40.00 and gave the stock an “outperform” rating in a report on Monday, May 11th. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $39.00.

Hedge Funds Weigh In On Artiva Biotherapeutics

Several institutional investors have recently made changes to their positions in the stock. Citadel Advisors LLC boosted its position in shares of Artiva Biotherapeutics by 419.3% during the 3rd quarter. Citadel Advisors LLC now owns 798,397 shares of the company’s stock worth $2,291,000 after purchasing an additional 644,658 shares in the last quarter. BNP Paribas Financial Markets increased its position in Artiva Biotherapeutics by 14,463.5% in the 3rd quarter. BNP Paribas Financial Markets now owns 118,547 shares of the company’s stock valued at $340,000 after buying an additional 117,733 shares in the last quarter. Renaissance Technologies LLC increased its position in Artiva Biotherapeutics by 46.8% in the 4th quarter. Renaissance Technologies LLC now owns 116,200 shares of the company’s stock valued at $498,000 after buying an additional 37,053 shares in the last quarter. Marshall Wace LLP acquired a new position in Artiva Biotherapeutics during the 4th quarter worth approximately $341,000. Finally, Jane Street Group LLC acquired a new position in Artiva Biotherapeutics during the 2nd quarter worth approximately $67,000.

About Artiva Biotherapeutics

Artiva Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of allogeneic “off-the-shelf” cell therapies for cancer. The company’s proprietary platform leverages natural killer (NK) cells engineered to express chimeric antigen receptors (CARs) or other targeting modalities, with the goal of delivering potent anti-tumor activity while minimizing the safety and supply limitations associated with patient-derived (autologous) approaches.

Artiva’s pipeline includes multiple lead product candidates designed to address both hematologic malignancies and solid tumors.